{"groups":[{"description":"Patients with baseline platelet counts \\>50,000 k/uL received lenalidomide (LEN) PO daily or QOD on days 1-21. If platelet counts fell below 50,000 k/uL during treatment, patients discontinued LEN and received eltrombopag olamine (ELT) PO daily or QOD until platelet counts \\> 50,000 k/uL were achieved, and then maintained for 2 weeks thereafter. If a platelet count \\>50,000 k/uL was maintained, patients discontinued ELT and resumed only LEN as a single agent (PO daily or QOD). If platelets fell below 50,000 k/uL a second time, LEN was stopped and ELT was re-initiated at the dose last given to the patient. Once platelet counts were \\>50,000 k/uL and maintained for 2 weeks, patients resumed LEN concurrently with ELT for all subsequent courses.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"FG000","title":"Arm A (Platelets > 50,000 k/uL) LEN Initiation"},{"description":"Patients with baseline platelet counts \\<50,000 k/uL received eltrombopag olamine (ELT) PO daily or QOD on days 1-28 until a platelet count \\>50,000 k/uL was achieved. Once a platelet count\\>50,000 k/uL was achieved the ELT dose was maintained for two weeks. After two weeks ELT was discontinued and LEN was started as in Arm A (i.e., eltrombopag olamine discontinued and lenalidomide started). Patients in Arm B were permitted to stay on ELT alone if a hematologic response on ELT was achieved as defined by the 2006 International Working Group (IWG) consensus criteria, or if baseline hemoglobin was \\>10.0 g/dL and didn't decrease while on study drug.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO","id":"FG001","title":"Arm B (Platelets < 50,000 k/uL) ELT Initiation With Potential LEN Combination"},{"description":"Patients in Arm B were permitted to stay on ELT alone if a hematologic response on ELT was achieved as defined by the 2006 International Working Group (IWG) consensus criteria, or if baseline hemoglobin was \\>10.0 g/dL and didn't decrease while on study drug.\n\nTreatment repeated every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nEltrombopag Olamine: Given PO Laboratory Biomarker Analysis: Correlative studies","id":"FG002","title":"Arm C (Platelets < 50,000 k/uL) ELT Monotherapy"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"From October 2012 through January 2020, 52 patients were enrolled in this multicenter study."}